Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Molecular profiling of ovarian carcinoma platinum-sensitive and -resistant cell lines (microRNAs)

ABSTRACT: Resistance to platinum compounds represents a major obstacle to the cure of ovarian carcinoma. The molecular profiling of drug-sensitive and drug-resistant cells may be helpful to clarify if altered expression of miRNAs can contribute to the drug-resistant phenotype. The expression pattern of miRNAs of three ovarian carcinoma cell lines was examined. The analysis revealed the modulation of several miRNAs in the two platinum-resistant cell lines as compared to parental platinum-sensitive cells. The integration of the information obtained through miRNA expression analysis may be useful to clarify the specific molecular alterations of factors and pathway favouring survival of tumor cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE58469 | GEO | 2018/06/26

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Molecular profiling of ovarian carcinoma platinum-sensitive and -resistant cell lines (gene expression)

Project description:Resistance to platinum compounds represents a major obstacle to the cure of ovarian carcinoma. The molecular profiling of drug-sensitive and drug-resistant cells may be helpful to clarify if altered gene expression can contribute to the drug-resistant phenotype. The expression pattern of three ovarian carcinoma cell lines was examined. The analysis revealed the modulation of several genes in the two platinum-resistant cell lines as compared to parental platinum-sensitive cells. The integration of the information obtained through gene expression analysis may be useful to clarify the specific molecular alterations of factors and pathway favouring survival of tumor cells.

2018-06-26 | GSE58470 | GEO

RNA-Seq of treatment response of platinum sensitive and platinum resistant ovarian cancer cells

Project description:Resistance to platinum-based chemotherapy is a clinical challenge in the treatment of ovarian cancer (OC) and limits survival. Therefore, innovative drugs against platinum-resistance are urgently needed. Our therapeutic concept is based on the conjugation of two chemotherapeutic compounds to a monotherapeutic pro-drug, which is taken up by cancer cells and cleaved into active cytostatic metabolites. Here, we explore the activity of the duplex-prodrug 5-FdU-ECyd, covalently linking 2'-deoxy-5-fluorouridine (5-FdU) and 3'-C-ethynylcytidine (ECyd), on platinum-resistant OC cells. RNA-Sequencing was used for characterization of 5-FdU-ECyd treated platinum-sensitive A2780 and isogenic platinum-resistant A2780cis.

2018-02-22 | GSE98230 | GEO

MicroRNA profiling of cisplatin-resistant and cisplatin-sensitive ovarian cancer cells

Project description:Platinum resistance is a major drawback in the treatment of ovarian cancer. Evidence suggests that microRNAs are key players in the initiation, progression, and drug resistance of cancer cells. However, the precise miRNAs dysregulated and contributing to platinum resistance in ovarian cancer cells have not been fully elucidated. Here, we conducted a miRNA expression profiling of cisplatin-sensitive (A2780) and cisplatin-resistant (CP20 and CIS) ovarian cancer cells to identify potential miRNAs involved in platinum resistance.

2020-11-20 | GSE161784 | GEO

Molecular profiling of ovarian carcinoma platinum-sensitive and -resistant cell lines

Project description:Molecular profiling of ovarian carcinoma platinum-sensitive and -resistant cell lines

| PRJNA252702 | ENA

Expression analysis of platinum sensitive and resistant epithelial ovarian cancer patient samples.

Project description:The objective of this work was to identify potential cancer biomarkers by analyzing microarray and protein expression data from platinum-sensitive and -resistant ovarian cancer patient samples. The gene expression profiles of the samples were ompared based on platinum sensitivity status and PARP levels.

2018-05-09 | GSE114206 | GEO

Unexpected roles of ATP11B in platinum resistance

Project description:Platinum compounds display clinical activity against a wide variety of solid tumors. However, resistance to these agents is a major limitation in cancer therapy. Reduced platinum uptake and increased platinum export are examples of resistance mechanisms that limit the extent of DNA damage. Here, we report the discovery and characterization of the role of ATP11B, a P-type ATPase membrane protein, in cisplatin resistance. ATP11B gene silencing restored the sensitivity of ovarian cancer cell lines to cisplatin in vitro. Combined therapy of cisplatin and ATP11B-siRNA significantly decreased cancer growth in mice bearing ovarian tumors derived from cisplatin-sensitive and -resistant cells. In vitro mechanistic studies on cellular platinum content and cisplatin efflux-kinetics indicated that ATP11B enhances the export of cisplatin from cells. The co-localization of ATP11B with fluorescent cisplatin and with vesicular trafficking proteins such as syntaxin-6 (STX6) and vesicular associated membrane protein 4 (VAMP4) strongly suggests that ATP11B contributes to secretory vesicular transport of cisplatin from Golgi to plasma membrane. In conclusion, silencing ATP11B expression might be a therapeutic strategy to overcome cisplatin resistance. We performed the transfection of control-siRNA and ATP11B-siRNA to both cisplatin-sensitive A2780-PAR and cisplatin-resistant A2780-CP20 cells respectively.

2013-01-23 | E-GEOD-43694 | biostudies-arrayexpress

Suppression of the chromatin remodeling protein CHD3 and platinum resistance in ovarian cancer

Project description:Epithelial ovarian cancer is the leading cause of death from gynecological malignancies. Currently platinum-based chemotherapy, coupled with a taxane based drug is the primary treatment for ovarian cancer. Approximately 25% of patients either present with or rapidly develop resistance to platinum based chemotherapy and all recurrent tumors ultimately become resistant. Epigenetic modifications have been associated with tumor formation and progression and may contribute to therapy response. We performed a methylation screen on a set of tumors and have found a number of genes and family members differentially methylated between resistant patients and sensitive patients. Here we show that loss of expression of CHD3, a member of the Mi-2/NuRD complex, causes increased resistance to platinum chemotherapy drugs. Additionally, ovarian cell lines transcriptionally silenced for CHD3 are more invasive, have migratory ability, and display a transformed epithelial to mesenchymal (EMT) phenotype. Taken together, we provide the first evidence of a role for CHD3 as an important epigenetic regulator of chemoresistance in ovarian cancer and hypothesize EMT as one of the underlying mechanisms. Furthermore, CHD3 expression might represent a therapy response predictor and could be a future therapeutic target for ovarian cancer. We have developed a method to profile genome wide methylation. 71 ovarian tumor samples and 9 normal tissue samples from individuals were analyzed for CpG methylation. Some of these regions were validated for their methylation as a proof of principle for the method. Kamalakaran S., et. al. Mol Oncol. 2011;5:77-92 (PMID: 21169070).

2012-05-14 | E-GEOD-33011 | biostudies-arrayexpress

Genome-wide mapping of H3K27ac and H3K9ac in platinum sensitive and resistant epithelial ovarian cancer cell lines

Project description:ChIP-seq for H3K27ac or H3K9ac was performed in different platinum sensitive and resistant epithelial ovarian cancer cell lines and in sensitive A2780 cells with shRNA induced knockdown of MBD3.

2021-07-26 | GSE172510 | GEO

Molecular analysis of platinum-resistant and -sensitive ovarian cacner based on RNA-Seq analysis

Project description:Ovarian cancer (OC) is the leading cause of death from gynecologic malignancies. The most difficult issue in the treatment of ovarian cancer is the eventual development of platinum resistance. Accumulating studies have shown that circRNAs are abnormally aberrantly expressed in tumors and play critical roles in tumor growth, metastasis, stemness and resistance to therapy.To identify circRNAs that play crucial roles in maintaining the platinum resistance of ovarian cacner, we performed RNA-seq analysis in platinum-resistant（n=9） and -sensitive（n=10） ovarian cacner tissues. Candidate genes were identified by bioinformatic analysis and literature review.

2024-05-30 | GSE214302 | GEO